Down 74% over five years while the S&P 500 rose 76%.
−3Long-term trend
OLMA's Quality Score rose 1 point on Mon, Nov 2, to -5.
Follow OLMA's trial news. Pro members can get an alert when Olema Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | A $205M loss |
| Latest filing | 8-K, Oct 15 |
ReportExpected to report Mon Nov 9, after the close. Every 3 months, a company tells everyone how much it sold and earned. It rose after 2 and fell after 2 of its last 4 reports, -0.4% on average. Past reports ›
After its last 4 reports it closed -0.4% on average, higher 2 of 4 times.
About 11 quarters
Director Cyrus Harmon sold 25,000 shares on Jul 24. 5 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
OLMA is #225 of 291 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 225 |
Net income over four quarters: OLMA -$205M, LXRX -$61.1M, ACHV -$114M, OCUL -$301M.
Expected to report Mon Nov 9, after the close (in 7 days). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The increase in R&D expenses was primarily related to increased spending on clinical development-related activities as we continue to advance palazestrant through late-stage clinical trials and OP-3136 in early-stage clinical studies, and increased personnel-related costs to support expanding development activities, including an increase in non-cash stock-based compensation expense of $5.2 million, mainly due to higher grant prices in 2026 and higher headcount.”
OLMA's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The increase in G&A expenses was primarily due to higher corporate-related costs that reflect continued investment in personnel and corporate infrastructure to support our expanding late-stage clinical development activities and anticipated future commercial operations, including an increase in non-cash stock-based compensation expense of $3.0 million, mainly due to higher grant prices in 2026, and an increase in professional fees of $1.8 million.”
From its results filing (SEC filing · Aug 10)
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 10, 2026 | -8.0% | -12.7% | -9.8% |
| May 12, 2026 | -2.1% | -6.0% | -13.2% |
| Mar 16, 2026 | +2.6% | +12.8% | -4.3% |
One insider sold $291K across 2 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: OLMA is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
OLMA scores -5 today, which Breakaway calls Poor. It is #225 of 291 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 74% over five years while the S&P 500 rose 76%. Cash lasts about 11 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
OLMA scores -5 today, which Breakaway calls Poor (below zero). That is #225 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind OLMA's -5.
One insider sold $291K across 2 filings in the last 6 months. No open-market buys on record. The newest is Cyrus Harmon, Director, who sold $146K on Jul 24. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.